Results 91 to 100 of about 16,189 (104)

Dimethyl Fumarate vs. Monomethyl Fumarate: Unresolved Pharmacologic Issues. [PDF]

Pharmaceutics
Kopincova J, Bernatova I.
europepmc   +1 more source

Efficacy and safety of disease-modifying oral drugs in treatment of relapsing-remitting multiple sclerosis: systematic review and network meta-analysis. [PDF]

Front Immunol
Zhao Y, Chen B, Zhao X, Yang R, He W, Li D, Sun Q, Zhang J, Liu X.   +8 more
europepmc   +1 more source

Oxidative and nitrosative damage in multiple sclerosis. [PDF]

Curr Opin Neurol
Prozorovski T, Meuth SG, Hartung HP, Berndt C.   +3 more
europepmc   +1 more source

A Randomised, Double-Blind Study Comparing the Gastrointestinal Tolerability of Tegomil Fumarate Versus Dimethyl Fumarate in Healthy Volunteers. [PDF]

Neurol Ther
Fonseca M, Bauzà Valverde G, Bendarraz A, Catalán Flores C, Sharma VM.   +4 more
europepmc   +1 more source

Diroximel Fumarate in the Treatment of Multiple Sclerosis

Neurodegenerative Disease Management, 2020
Diroximel fumarate (DRF) is a new emerging therapy for patients with multiple sclerosis. The levels of its active metabolite, monomethyl fumarate, are bioequivalent to the levels generated from dimethyl fumarate (DMF) treatment.
Tobias Sejbaek, Elise Jonasson
exaly   +2 more sources